GlassScriptPhysician profile
Samina Naseer
NPI 1245406149
$5,060.77
in general payments reported to CMS, 2019-2025
39 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $276 · 2021: $938 · 2022: $1,221 · 2023: $1,246 · 2024: $1,025 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $979.98 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $665.93 | 2021-2024 | |
| Lilly USA, LLC | $410.77 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $316.34 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $259.55 | 2020-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $239.85 | 2021-2024 | |
| Organogenesis INC. | $220.15 | 2021-2025 | Apligraf, Puraply Wound Matrix, Puraply |
| Smith+Nephew, INC. | $184.36 | 2019-2025 | Renasys Go V2 Home, Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $177.64 | 2020-2022 | |
| Astellas Pharma US INC | $169.43 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.00 | 2021-2024 | Jardiance, Synjardy, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $142.23 | 2021-2022 | |
| Pfizer INC. | $121.40 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $112.25 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $89.64 | 2020-2024 | Airsupra, Breztri, Farxiga |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $88.59 | 2023 | Korlym |
| Lifenet Health | $64.91 | 2023 | |
| Merck Sharp & Dohme LLC | $57.53 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $54.65 | 2019-2024 | Nuzyra |
| Integra Lifesciences Corporation | $48.85 | 2022-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Phathom Pharmaceuticals, INC. | $46.13 | 2023-2024 | Voquezna |
| Tactile Systems Technology INC | $45.63 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Abiomed | $44.19 | 2023-2024 | Impella |
| Kerecis Limited | $41.35 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $35.81 | 2023-2025 | Gvoke Hypopen |
| Urgo Medical North America, LLC | $31.55 | 2024 | Urgok2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.30 | 2024-2025 | Xifaxan |
| Cumberland Pharmaceuticals, INC. | $28.21 | 2022-2024 | Vibativ |
| Takeda Pharmaceuticals U.S.A., INC. | $26.57 | 2020 | |
| Kci USA, INC. | $25.66 | 2021 | |
| Solventum Corporation | $23.38 | 2024 | Promogran Prisma, 3m Cavilon, Activ.A.C. |
| Melinta Therapeutics, LLC | $22.57 | 2019 | |
| Bsn Medical INC | $22.10 | 2025 | |
| Amarin Pharma, INC. | $17.71 | 2022 | |
| Misonix INC | $15.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.53 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.08 | 2024 | Edarbi |
| Novartis Pharmaceuticals Corporation | $12.80 | 2022 | |
| Biogen, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samina Naseer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.